30.58
전일 마감가:
$32.31
열려 있는:
$32.24
하루 거래량:
93,034
Relative Volume:
0.69
시가총액:
$483.69M
수익:
-
순이익/손실:
$-61.23M
주가수익비율:
-2.2619
EPS:
-13.5194
순현금흐름:
$22.49M
1주 성능:
-4.82%
1개월 성능:
-12.65%
6개월 성능:
+68.58%
1년 성능:
+76.25%
Assembly Biosciences Inc Stock (ASMB) Company Profile
명칭
Assembly Biosciences Inc
전화
(833) 409-4583
주소
TWO TOWER PLACE, SOUTH SAN FRANCISCO
ASMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences Inc
|
30.58 | 511.05M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Guggenheim | Buy |
| 2024-09-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Neutral |
| 2021-09-02 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-10-19 | 개시 | Truist | Buy |
| 2019-10-16 | 개시 | Mizuho | Buy |
| 2018-11-19 | 개시 | Leerink Partners | Outperform |
| 2018-10-08 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | 개시 | Robert W. Baird | Outperform |
| 2018-04-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | 개시 | Jefferies | Buy |
| 2017-05-30 | 개시 | Chardan Capital Markets | Buy |
모두보기
Assembly Biosciences Inc 주식(ASMB)의 최신 뉴스
(ASMB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Stock Price Up 4% – Time to Buy? - Defense World
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Trading 4% HigherHere's What Happened - MarketBeat
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB - Defense World
Assembly Biosciences stock jumps after Wall Street says Gilead opt-in 'significantly de-risks' genital herpes programs - MSN
Technical Reactions to ASMB Trends in Macro Strategies - Stock Traders Daily
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Yahoo Finance
Why Assembly Biosciences Inc. stock remains a top recommendationVolume Spike Alerts & Outstanding Growth Stocks - bollywoodhelpline.com
Assembly Biosciences price target raised to $40 from $29 at Mizuho - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6%What's Next? - MarketBeat
GILD Exercises Option to License Assembly Bio's Herpes Programs - Eastern Progress
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - BioSpace
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Sahm
Assembly Biosciences (NASDAQ:ASMB) Receives Buy Rating from HC Wainwright - Defense World
Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says HC Wainwright - MSN
Gilead exercises option for Assembly Bio’s herpes treatment programs By Investing.com - Investing.com South Africa
HC Wainwright & Co. Reiterates Assembly Biosciences (ASMB) Buy Recommendation - Nasdaq
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Asianet Newsable
Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Assembly Biosciences rises as Gilead opts to license co's HSV therapies - TradingView — Track All Markets
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
ASMB: HC Wainwright & Co. Reiterates Buy Rating with $50 PT | AS - GuruFocus
Gilead exercises license for Assembly Biosciences herpes programs - Seeking Alpha
Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Program - PharmiWeb.com
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal - GuruFocus
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
Gilead exercises option for Assembly Bio's herpes treatment programs - StreetInsider
Assembly Biosciences (ASMB) Price Target Increased by 24.84% to 48.70 - Nasdaq
Financial Analysis: Teva Pharmaceutical Industries (NYSE:TEVA) versus Assembly Biosciences (NASDAQ:ASMB) - Defense World
Can Assembly Biosciences Inc. stock beat analyst upgradesTrade Risk Assessment & Fast Entry Momentum Alerts - Улправда
What risks investors should watch in Assembly Biosciences Inc. stockJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials - MSN
How Assembly Biosciences Inc. stock performs in rising dollar environmentEntry Point & Reliable Price Breakout Alerts - Улправда
How resilient is Assembly Biosciences Inc. stock in market downturnsEarnings Summary Report & Scalable Portfolio Growth Methods - Улправда
Why Assembly Biosciences Inc. stock could see breakout soon2025 Trade Ideas & Risk Managed Trade Strategies - Улправда
Recap Report: How Assembly Biosciences Inc. stock performs in rising dollar environmentQuarterly Trade Report & Community Verified Watchlist Alerts - Улправда
Can Assembly Biosciences Inc. stock resist market sell offsJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - Улправда
Assembly Biosciences Earnings Notes - Trefis
Assembly Biosciences completes key phase 1a study on ABI-6250 - MSN
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Assembly Biosciences Completes Key Phase 1a Study on ABI-6250 - TipRanks
(ASMB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JANUS HENDERSON GROUP PLC Expands Stake in Assembly Biosciences Inc - GuruFocus
Assembly Biosciences (ASMB) Receives a Buy from Guggenheim - The Globe and Mail
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data By Investing.com - Investing.com South Africa
Jefferies raises Assembly Biosciences stock price target to $62 on HSV data - Investing.com Nigeria
Assembly Biosciences Inc (ASMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):